ArticleInternal and emergency medicine2015
The involvement of T regulatory lymphocytes in a cohort of lupus nephritis patients: a pilot study.
Article in Internal and emergency medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Targeting FOXP3 and Regulatory T Cells in Systemic Lupus Erythematosus: Emerging Therapeutic Strategies and Clinical Prospects.Journal of cellular biochemistry · 2026Review
- Low-Dose Interleukin-2 as an Alternative Therapy for Refractory Lupus Nephritis.Rheumatology and therapy · 2021Article
- Immunohistochemical Expression of FOXP3+ Regulatory T Cells in Proteinuric Primary Glomerulopathies.International journal of nephrology · 2021Article
- [Genetically modified regulatory T cells: therapeutic concepts and regulatory aspects].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2020Review
- Autoimmunity and organ damage in systemic lupus erythematosus.Nature immunology · 2020Review
- Pattern of sleep dysfunction in systemic lupus erythematosus: a cluster analysis.Clinical rheumatology · 2019Article
- Inflammation and Dysmetabolism in Systemic Autoimmune Diseases.Journal of immunology research · 2019Article
- Regulatory T cells in the treatment of disease.Nature reviews. Drug discovery · 2018Review
- Regulatory T cells in acute and chronic kidney diseases.American journal of physiology. Renal physiology · 2018Review
- FOXP3Pediatric nephrology (Berlin, Germany) · 2018Article
- Regulatory T cells in renal disease.Clinical & translational immunology · 2018Review
- Empowering Regulatory T Cells in Autoimmunity.Trends in molecular medicine · 2016Review
- The Changing Landscape of Renal Inflammation.Trends in molecular medicine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T regulator lymphocytes (Tregs) play a key role in the maintenance of immune tolerance and in the development of autoimmune diseases. Expression of Foxp3 is specific for Tregs, and can be used for the identification of these cells. This study investigated the variations of Tregs Foxp3+ in the kidney biopsies inflammatory infiltrate of different lupus nephritis classes compared to that of ANCA glomerulonephritis, acute tubulointerstitial nephritis and nephroangiosclerosis. Sections of paraffin-embedded tissue have been stained by immunohistochemistry with anti-CD3 and anti-FoxP3 antibodies. We find that the ratio of FoxP3+/CD3+ cells is significantly lower in patients with lupus nephritis class IV and in patients with vasculitides than in the course of nephroangiosclerosis, tubulointerstitial nephritis and lupus nephritis class V. The data presented herein demonstrate a decrease of FoxP3+ Treg cells in the inflammatory infiltrate of lupus nephritis, particularly during the most active phases of lupus nephritis, as observed in the course of a IV class nephritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.